IRCCS CROB

At IRCCS CROB in Rionero in Vulture, research in Hemic and Lymphatic Diseases focuses on Acute Myeloid Leukemia with FLT3 mutation. The trials are aimed at improving treatment outcomes by identifying patients who may benefit from earlier treatment intensification and more personalized care.

• Acute Myeloid Leukemia with FLT3 mutation
• Using biomarkers such as peripheral blast clearance to guide therapy decisions
• Evaluating whether tailored treatment strategies can improve event-free survival

This work reflects a strong interest in refining hematology care through more precise treatment selection and better prediction of response.

The Neoplasms portfolio at IRCCS CROB covers several solid tumors, including advanced non-small-cell lung cancer and urothelial cancer. The studies are designed to test new treatment combinations and maintenance approaches that may extend survival and delay disease progression.

• Advanced non-small-cell lung cancer in the first-line setting
• Urothelial cancer after response to platinum-based chemotherapy
• Assessing whether treatment combinations or maintenance therapy improve overall survival and progression-free survival

These trials highlight ongoing efforts in oncology to improve outcomes for patients with hard-to-treat cancers through more effective treatment strategies.

Clinical research at the site also includes genitourinary cancers, with attention to urothelial cancer and prostate cancer. The studies are exploring ways to improve disease control, support longer remission, and clarify the benefit of adding treatment components in local and advanced disease.

• Urothelial cancer maintenance treatment after chemotherapy
• Prostate cancer outcomes after stereotactic body radiation therapy
• Measuring whether treatment approaches improve progression-free survival and biochemical disease-free survival

This area brings together treatment evaluation and disease-control research, supporting more informed care for patients with urologic malignancies.

Another active research theme at IRCCS CROB is prostate cancer, where investigators are examining whether combining local radiation with hormonal treatment can improve control of the disease. The goal is to determine if adding supportive therapy leads to better long-term outcomes than radiation alone.

• Prostate cancer treated with stereotactic body radiation therapy
• Comparing radiation alone with radiation plus androgen deprivation therapy
• Focusing on improved biochemical disease-free survival

This research supports a broader effort in radiation oncology to optimize treatment combinations for better disease control.